Awakn Life Sciences Corp. Receives U.K. MHRA's Innovative Licensing for its Breakthrough Therapy for Severe Alcohol Use Disorder

Awakn Life Sciences Corp., a biotechnology company specializing in developing addiction therapies with a primary focus on Alcohol Use Disorder (AUD), announces that U.K. MHRA has granted Innovation Passport through Innovative Licensing and Access Pathway (ILAP) for ketamine-assisted therapy, aimed at treating Severe Alcohol Use Disorder (AUD). Awakn is strengthening its position in revolutionizing addiction treatment.

Publish Date: 08-02-2023 Source: Awakn Life Sciences Corp.

Alcohol Use Disorder (AUD) is a pathological condition characterized by persistent and excessive alcohol consumption, leading to a diminished ability to limit or abstain from alcohol use despite adverse consequences in one’s social, occupational, or medical domain. The disease is characterized by several key symptoms, including: 1. Craving – an intense urge to consume alcohol 2. Loss of control – an inability to cease alcohol consumption once initiated 3. Negative emotional state – feelings of anxiety and irritability when abstaining from alcohol. Several factors increase the chances of developing an alcohol use disorder, such as Family history of substance abuse and alcohol use disorder, Accessibility of alcohol, Excessive alcohol consumption, Binge drinking, Permissive cultural attitudes towards alcohol, Childhood abuse, Childhood conduct or mood disorders, Co-occurring mental health conditions such as depression and PTSD, Impulsivity. Diagnosis of AUD is made through a comprehensive evaluation and assessment of symptoms, as outlined in the Diagnostic and Statistical Manual of Mental Disorders. The severity of the disorder is determined based on the number of criteria met and can range from mild (2-3 criteria), moderate (4-5 criteria) to severe (6 or more criteria). The U.S. Food and Drug Administration approved three drugs for managing AUD, including naltrexone, acamprosate, and disulfiram, which aid in reducing alcohol consumption and preventing relapse.

According to a national survey in the USA, 14.1 million adults ages 18 and older (5.6% of this age group) had alcohol use disorder (AUD).

However, the current Alcohol Use Disorder (AUD) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (AD04, Ketamine, Canakinumab, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Alcohol Use Disorder (AUD) treatment. The key companies in the advanced development stage are Adial Pharmaceuticals, Awakn Life Sciences, Novartis Pharmaceuticals, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Alcohol Use Disorder (AUD) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2022 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.